Canadian Medical Association Journal
March 2, 2025
Daniel T. Myran, Jennifer Xiao, Nicholas Fabiano et al.
8 citations
Background: Although clinical trials involving psychedelic-assisted psychotherapy have not observed short-term increases in the risk of death, limited data exist on mortality associated with hallucinogen use outside of controlled trial settings. We sought to determine whether people with an emergency department visit or hospital admission involving hallucinogen use were at increased risk of...
Canadian Medical Association Journal
August 20, 2023
Cyrille de Halleux, D. Juurlink
CMAJ | August 21, 2023 | Volume 195 | Issue 32 E1075 Nitrous oxide (N2O) has become a popular but dangerous recreational drug. Colloquially referred to as “laughing gas,” it was first used therapeutically in 1844 for patients undergoing dental surgery.1 Although a weak anesthetic, it remains in use today, especially for pediatric and dental procedures.2 Its recreational use is now recognized as...
Canadian Medical Association Journal
December 18, 2022
Kevin Zannese
9 citations
Alberta will soon become the first province to regulate psychedelic-assisted therapy. But, as with cannabis, momentum for medical access to psychedelics is outpacing research to guide their use. Earlier this year, Health Canada amended its Special Access Program to allow physicians to request
Canadian Medical Association Journal
November 14, 2021
Greg Basky
7 citations
Research interest in the therapeutic use of psilocybin, or "magic mushrooms," is growing alongside a "wild west" of dispensaries in Canada and the United States. The past decade has seen a revival of research exploring the clinical use of psychedelics in treating depression, addiction,
Canadian Medical Association Journal
February 16, 2016
Wm. Jeptha Davenport
14 citations
Tupper and colleagues highlight reasons for renewed interest in the use of psychedelic drugs as adjuncts to psychotherapy.[1][1] Clinicians have an interest in extending research into headache medicine, especially the treatment of cluster headaches (prevalence roughly 0.1%) when episodes are
Canadian Medical Association Journal
September 8, 2015
Kenneth W. Tupper, Evan Wood, Richard Yensen et al.
189 citations
In clinical research settings around the world, renewed investigations are taking place on the use of psychedelic substances for treating illnesses such as addiction, depression, anxiety and posttraumatic stress disorder (PTSD). Since the termination of a period of research from the 1950s to the
Canadian Medical Association Journal
August 4, 2015
Erika Dyck
25 citations
Psychedelics fell from medical grace nearly half a century ago, but recent activity suggests that some researchers have "high hopes" for their return.[1][1],[2][2] Over 60 years ago, Albert Hofmann at Sandoz Pharmaceutical Laboratories in Switzerland first synthesized lysergic acid diethylamide
Canadian Medical Association Journal
October 8, 2007
Matthew Kopala
1 citation
Studies have suggested that as many as 1 in 4 cannabis users may be genetically at risk for developing schizophrenia or a related psychotic disorder. Now, a new study reveals all users are at risk.[1][1] Given recent United Nations' statistics citing Canada as the industrial world's leading